Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting.

Rosencher N, Samama CM, Feuring M, Brueckmann M, Kleine E, Clemens A, Frostick S.

Thromb J. 2016 Apr 1;14:8. doi: 10.1186/s12959-016-0082-4. eCollection 2016.

2.

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.

Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Kent AP, Pogue J, Spahr J, Clemens A, Noack H, Diener HC, Wallentin L, Yusuf S, Connolly SJ.

Europace. 2016 Mar 3. pii: euv312. [Epub ahead of print]

PMID:
26944733
3.

Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.

Douketis JD, Healey JS, Brueckmann M, Fraessdorf M, Spyropoulos AC, Wallentin L, Oldgren J, Reilly P, Ezekowitz MD, Connolly SJ, Yusuf S, Eikelboom JW.

Thromb Res. 2016 Mar;139:77-81. doi: 10.1016/j.thromres.2016.01.004. Epub 2016 Jan 9.

PMID:
26916299
4.

Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.

Majeed A, Hwang HG, Eikelboom JW, Connolly S, Wallentin L, Feuring M, Brueckmann M, Noack H, Yusuf S, Schulman S.

Thromb Res. 2016 Apr;140:81-8. doi: 10.1016/j.thromres.2016.02.005. Epub 2016 Feb 22.

PMID:
26908016
5.

Diagnostic and Long-Term Prognostic Value of Sensitive Troponin I in Symptomatic Patients Suspected of Acute Heart Failure.

Behnes M, Espeter F, Hoffmann U, Lang S, Brueckmann M, Akin I, Borggrefe M, Bertsch T, Weiss C, Neumaier M, Ahmad-Nejad P.

Clin Lab. 2015;61(11):1737-47.

PMID:
26732000
6.

Reply: Anticoagulant-Related Nephropathy.

Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L.

J Am Coll Cardiol. 2015 Dec 15;66(23):2682. doi: 10.1016/j.jacc.2015.09.080. No abstract available.

PMID:
26670072
7.

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.

Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ.

Europace. 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. Epub 2015 Oct 18. Review.

PMID:
26481149
8.

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.

Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F.

Thromb Haemost. 2016 Feb 29;115(3):562-9. doi: 10.1160/TH15-07-0531. Epub 2015 Oct 15.

PMID:
26467062
9.

Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).

Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, Brueckmann M, Sacco RL; RE-SPECT ESUS Investigators.

Int J Stroke. 2015 Dec;10(8):1309-12. doi: 10.1111/ijs.12630. Epub 2015 Sep 30.

PMID:
26420134
10.

Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).

Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, Connolly SJ, Yusuf S, Ezekowitz MD.

Am J Cardiol. 2015 Oct 15;116(8):1204-9. doi: 10.1016/j.amjcard.2015.07.032. Epub 2015 Jul 28.

PMID:
26282726
11.

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.

Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS.

Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.

PMID:
26093161
12.

Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I.

Hoffmann U, Espeter F, Weiß C, Ahmad-Nejad P, Lang S, Brueckmann M, Akin I, Neumaier M, Borggrefe M, Behnes M.

BMC Cardiovasc Disord. 2015 Jun 14;15:50. doi: 10.1186/s12872-015-0026-0.

13.

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.

Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L.

J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.

PMID:
26065986
14.

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.

Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ.

Thromb Haemost. 2015 Mar;113(3):625-32. doi: 10.1160/TH14-04-0305. Epub 2014 Dec 4.

PMID:
25472710
15.

Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".

Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S.

Circulation. 2014 Sep 2;130(10):e95. doi: 10.1161/CIRCULATIONAHA.114.010280. No abstract available.

16.

Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.

Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, Brueckmann M, Borggrefe M, Hoffmann U.

Crit Care. 2014 Sep 5;18(5):507. doi: 10.1186/s13054-014-0507-z.

17.

Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?

Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY.

Ann Med. 2014 Dec;46(8):672-8. doi: 10.3109/07853890.2014.952327. Epub 2014 Aug 31.

PMID:
25174259
18.

Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study".

Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S.

Circulation. 2014 Aug 26;130(9):e85. doi: 10.1161/CIRCULATIONAHA.114.010275. No abstract available.

19.

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S.

Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2.

20.

Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.

Clemens A, Noack H, Brueckmann M, Lip GY.

PLoS One. 2014 Jun 9;9(6):e99276. doi: 10.1371/journal.pone.0099276. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e109437.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk